Mu Yuan （ An Hui ） Yao Ye You Xian Gong Si

A single-center, randomized, open, two-period crossover, single-dose design was used to compare the differences in absorption extent and absorption rate between benzbromarone tablets (specification: 50 mg) provided by Muyuan (Anhui) Pharmaceutical Co., Ltd. and benzbromarone tablets (trade name: Urinorm®, specification: 50 mg) certified by Toeiyo Co., Ltd. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of benzbromarone tablets (specification: 50 mg) provided by Muyuan (Anhui) Pharmaceutical Co., Ltd.

Primary objective: This study aims to study the pharmacokinetic characteristics of rosuvastatin ezetimibe tablets (I) (10 mg/10 mg) developed by Muyuan (Anhui) Pharmaceutical Co., Ltd. and produced by Xinxiang Changle Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; Rosuvastatin ezetimibe tablets (I) (SUVREZA®, 10 mg/10 mg) certified by Sanofi-Aventis France and produced by Sanofi Winthrop Industrie-Tours was used as the reference preparation to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations and evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation after single fasting and postprandial oral administration in healthy subjects.